Astellas fleshes out more PhIII data for Claudin 18.2 drug
Just weeks after unveiling the first detailed late-stage data on its CLDN18.2 drug, Astellas is beefing up the data package with results from a second Phase III trial.
We already knew that adding Astellas’ zolbetuximab to a chemotherapy regimen called CAPOX spurred a statistically significant improvement in progression-free survival for stomach cancer patients, but the company is now specifying by how much. The combination of zolbetuximab plus CAPOX (a regimen that includes capecitabine and oxaliplatin) reduced the risk of progression or death by 31.3% (p=0.0007), meeting the primary endpoint.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters